Everything below concerns Lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
=== Messenger RNA (mRNA) carries genetic information that directs protein synthesis === The concept of messenger RNA emerged during the late 1950s, and is associated with Crick's description of his "central dogma of molecular biology", which asserted that DNA led to the formation of RNA, which in turn led to the synthesis of proteins. During the early 1960s, sophisticated genetic analysis of mutations in the lac operon of E. coli and in the rII locus of bacteriophage T4 were instrumental in defining the nature of both messenger RNA and the genetic code. The short-lived nature of bacterial RNAs, together with the highly complex nature of the cellular mRNA population, made the biochemical isolation of mRNA very challenging. This problem was overcome in the 1960s by the use of reticulocytes in vertebrates, which produce large quantities of mRNA that are highly enriched in RNA encoding alpha- and beta-globin (the two major protein chains of hemoglobin). The first direct experimental evidence for the existence of mRNA was provided by such a hemoglobin synthesizing system.
=== Singles === "Life" (1999) "Believer" (1999) "Too Late Tonight" (1999) "Me And My Melody" (2000) "All Will Wait" (2000) "You Are" (2002) "Everlasting Change" (2002) "Life On Mars" (2002) "Let Her Down Easy" (2003) "Words" (2007) "Why Do You Run" (2007) "Come On" (2010) "Broken Dancer" (2010) "The High Life" (2011) "Seven Odd Years" (2012)
Seventeen yachts and 167 crew started the first race of 27,500 nmi (50,900 km), which began from Portsmouth, United Kingdom, on 8 September 1973. Approximately 3000 spectator boats set out to witness the historic start. The first race was won by Mexican amateur Ramón Carlín in a Swan 65 yacht, Sayula II. Sayula II was followed by Adventure, Grand Louis and Kriter. The original course was designed to follow the route of the square riggers, which had carried cargo around the world during the 19th Century. From 2001 the ownership of the race was taken over by Volvo and Volvo Cars and the race was renamed the 'Volvo Ocean Race'. Stopover ports were added in Germany, France, and Sweden being Volvo's three biggest car markets in Europe. Winning the race does not attract a cash prize, as the feat of competing is presented as sufficient reward. Many of the crew in the Volvo Ocean Race race crew other professional teams in other high-profile events, such as the Olympic Games, Sydney to Hobart Yacht Race, the America's Cup, or the Fastnet Race. The worst weather conditions are usually encountered in the Southern Ocean where waves sometimes top 150 feet (46 m) and winds can reach 70 knots (130 km/h). The 2017–18 race covered 45,000 nautical miles, which is the longest route in its history.
=== Appeal === In January 2024, Letby applied to the Court of Appeal for permission to challenge her convictions, but this was refused by a single judge. She renewed her application, and at a three‑day hearing in April 2024 her legal team advanced four grounds of appeal relating to the trial judge's rulings. In May 2024, a panel comprising Dame Victoria Sharp, Lord Justice Holroyde and Mrs Justice Lambert refused permission to appeal. As part of the appeal, Letby's counsel, Ben Myers, again challenged the admission of evidence from paediatrician Evans, arguing that it should have been excluded on the basis that Evans had been "dogmatic and biased". The appeal judges rejected this, finding that Evans did not lack impartiality, was suitably qualified to give expert evidence, and that it was for the jury to assess its weight. A second ground of appeal concerned the medical evidence relating to alleged fatal air injections, which the defence described as "very weak". A third ground argued that the trial judge had erred in directing the jury that they could convict even if they were uncertain about the precise method used in each case. The final ground alleged that the judge had failed to investigate a question of juror impartiality. All four grounds were dismissed, with the Court concluding in its written judgement that the trial had been "thoughtful, fair, comprehensive and correct" and that none of the challenges raised by the defence were "arguable".
=== Interactions === alcohol - may lower the antidiuretic effect carbamazepine, chloropropamide, clofibrate, tricyclic antidepressants and fludrocortisone may raise the antidiuretic effect lithium, demeclocycline, heparin or norepinephrine may lower the antidiuretic effect vasopressor effect may be higher with the concurrent use of ganglionic blocking medications
Sources: en.wikipedia.org
==== Estrogens (estrogen receptor agonists) ==== Conjugated estrogens (conjugated equine estrogens; CEEs; Premarin) – estrogen (estrogen receptor agonist) – atrophic vaginitis, dyspareunia [132] Conjugated estrogens oral (Enjuvia; synthetic conjugated estrogens) – estrogen (estrogen receptor agonists) – atrophic vaginitis [133] Conjugated estrogens/bazedoxifene (Aprela; bazedoxifene acetate/conjugated estrogens; bazedoxifene/conjugated estrogens; bazedoxifene/Premarin; BZA/CE; CE/BZA; conjugated estrogens/bazedoxifene acetate; Duavee; Duavive; Premarin/bazedoxifene; SERM + Premarin) – combination of conjugated estrogens (estrogen) and bazedoxifene (selective estrogen receptor modulator (SERM)) – atrophic vaginitis [134] Estradiol (Estrofem; Innofem; oral estradiol; Vagifem; vaginal estradiol) – estrogen (estrogen receptor agonist) – atrophic vaginitis [135] Estradiol transdermal micro patch (Estradot; Minivelle; Vivelle-Dot) – estrogen (estrogen receptor agonist) – atrophic vaginitis [136] Estradiol vaginal (E2; 17β-estradiol; Estradiol VagiCap; Imvexxy; Joyesta; TX-12-004-HR; TX-004HR; VagiCap; Yuvvexy) – estrogen (estrogen receptor agonist) – atrophic vaginitis [137] Estradiol acetate (Estrace; estradiol acetate intravaginal ring; estradiol acetate IVR; Femring; Menoring) – estrogen (estrogen receptor agonist) – atrophic vaginitis [138] Estriol succinate vaginal gel (6α-hydroxyestradiol; Blissel; Gelistrol) – estrogen (estrogen receptor agonist) – atrophic vaginitis [139] Estriol/lactobacillus (estriol-Lactobcillus acidophilus mixt.; estriol/lyophilised lactobacilli; Gynoflor; ultra-low dose estrogen/lactobacillus) – combination of estriol (estrogen) and lactobacillus (probiotic) – atrophic vaginitis [140] Ospemifene (FC-1271a; Ophena; Osphena; Senshio) – selective estrogen receptor modulator (SERM) – atrophic vaginitis, dyspareunia [141]
== Disease relevance == Homozygous or compound heterozygous mutations in 3-phosphoglycerate dehydrogenase cause Neu–Laxova syndrome and phosphoglycerate dehydrogenase deficiency. In addition significantly shortening lifespan, PHGDH deficiencies are known to cause congenital microcephaly, psychomotor retardation, and intractable seizures in both humans and rats, presumably due to the essential signaling within the nervous system that serine, glycine, and other downstream molecules are intimately involved with. Treatment typically involves oral supplementation of serine and glycine and has been shown most effective when started in utero via oral ingestion by the mother. Mutations that result in increased PHGDH activity are also associated with increased risk of oncogenesis, including certain breast cancers. This finding suggests that pathways providing an outlet for diverting carbon out of glycolysis may be beneficial for rapid cell growth. It has been reported that PHGDH can also catalyze the conversion of alpha-ketoglutarate to 2-Hydroxyglutaric acid in certain variants. Thus, a mutation in the enzyme is hypothesized to contribute to 2-Hydroxyglutaric aciduria in humans, although there is debate as to whether or not this catalysis is shared by human PHGDH. Research results suggest that PHGDH could serve as a blood biomarker of Alzheimer's disease.
=== Side reactions === The three main side reactions that produce impurities have in common that they decompose urea. Urea hydrolyzes back to ammonium carbamate in the hottest stages of the synthesis plant, especially in the stripper, so residence times in these stages are designed to be short. Biuret is formed when two molecules of urea combine with the loss of a molecule of ammonia.
Richards echoed this sentiment, writing in a 2007 review, "[psychedelic] mushroom use may constitute one technology for evoking revelatory experiences that are similar, if not identical, to those that occur through so-called spontaneous alterations of brain chemistry." A group of researchers from Johns Hopkins School of Medicine led by Roland Griffiths conducted a study to assess the immediate and long-term psychological effects of the psilocybin experience, using a modified version of the mystical experience questionnaire and a rigorous double-blind procedure. When asked in an interview about the similarity of his work to Leary's, Griffiths explained the difference: "We are conducting rigorous, systematic research with psilocybin under carefully monitored conditions, a route which Dr. Leary abandoned in the early 1960s." Experts have praised the National Institute of Drug Abuse-funded study, published in 2006, for the soundness of its experimental design. In the experiment, 36 volunteers with no experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions; the methylphenidate sessions served as a control and psychoactive placebo. The degree of mystical experience was measured using a questionnaire developed by Ralph W. Hood; 61% of subjects reported a "complete mystical experience" after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate.
== External links == The MEROPS online database for peptidases and their inhibitors: Cysteine Peptidases Archived 2017-04-04 at the Wayback Machine Cysteine+endopeptidases at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.